Are you more likely to initiate a calcium channel blocker rather than a beta-blocker as first-line therapy in patients with symptomatic nonobstructive hypertrophic cardiomyopathy, in light of emerging randomized data suggesting potential physiologic advantages with verapamil?
Bjerregaard et al., PMID 41778690
Community PollStarted
Are you more likely to initiate a calcium channel blocker rather than a beta-blocker as first-line therapy in patients with symptomatic nonobstructive hypertrophic cardiomyopathy?
33 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet Member
Cardiology · The George Washington University Hospital
Answered on
Verapamil, in my experience, has a far greater incidence of side effects, especially at moderate to high doses.
Join for free or sign in to see the full answer